Spero Therapeutics to Present at Investor Conferences in March
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that its CEO, Ankit Mahadevia, M.D., will present at two upcoming investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that its CEO, Ankit Mahadevia, M.D., will present at two upcoming investor conferences in March 2021. The events include the Cowen 41st Annual Healthcare Conference on March 1, and the Oppenheimer 31st Annual Healthcare Conference on March 16. The presentations will focus on Spero's development of treatments for multi-drug resistant bacterial infections and rare diseases, including its lead candidate, tebipenem HBr, aimed at treating complicated urinary tract infections.
Details
News Market Reaction – SPRO
The recorded move for SPRO in the trading session of this news was -4.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present at the following investor conferences in March 2021:
The Cowen 41st Annual Healthcare Conference
Panel Name: Respiratory and Infections Panel
Panel Presentation Date and Time: Monday, March 1st at 10:20 – 11:20 AM EST
Oppenheimer 31st Annual Healthcare Conference
Corporate Presentation Date and Time: Tuesday, March 16th at 10:00 – 10:30 AM EST
Webcasts of corporate presentations may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. Replays of corporate presentations will be archived on the website for 90 days following the conclusion of each event.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Spero Investor and Media Contact:
Sharon Klahre
Vice President, Investor Relations
857-242-1547
IR@sperotherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.